These recent stories (from The Alliance for Natural Health-USA) are just a small part of the total story of the alliance between government and the drug companies (Pharma).
If one has a prognosis of death I say let that person take whatever, and try whatever they want.
Obamacare is a huge gift to the insurance companies and Big Pharma. It’s funny to hear so called “progressives” sing its praises.
3D printing is revolutionizing manufacturing already. From food to guns, the old business models are being undermined. Information is spilling out all over the place, information one can now hold in one’s hands.
It is interesting to me how wedded some people are to the idea that Obamacare is not a crony capitalist disaster. I understand why. It is the president’s signature piece of legislation. It has long been the dream of many in this country to implement nationalized healthcare. To acknowledge that what at first appeared to be an important political victory is likely anything but, is a hard pill to swallow.
If Obamacare fails it also means that Obama fails historically, and that is also very difficult.
Can he? I think the real question is – should he?
Obamacare is a bundle of crony capitalist red tape which will make your life more difficult. There are exceptions of course. If one is a drug company there is a good chance that one is going to make a ton of money with Obamacare, so your life might get better. But for most of us, this won’t be the case.
The pharmaceutical lobby is the most influential in Washington DC according to a recent survey by APCO Worldwide.
Another good one from the Examiner.
Putting aside that the author repeatedly refers to “excessive profits” (who is he to determine what is excessive? In fact I’d say that there is no such thing – in a free market) and his misunderstanding of the Big Oil tax breaks (they are not subsidies, still market distorting, but not subsidies) and the other partisan talking points, he correctly identifies how Medicare Part D has become a direct revenue line from tax payers to the bottom line of the large drug companies, and the attached graph is worth a look.